CONNECTing to LungCare
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of California, San Francisco
About this trial
This study evaluates a smoking cessation intervention (CONNECTing to LungCare) for improving shared decision-making conversations about smoking cessation and lung cancer screening between patients and providers. Shared decision making is a patient care model in which providers offer information regarding risks and benefits, patients express their values and preferences, and then healthcare decisions are jointly discussed between the patient and provider. Patient education, aided by decision support tools, can increase patients' knowledge, decrease their decisional conflict, promote decision making, and improve the patients' perception of risk. CONNECTing to LungCare is an interactive education intervention that addresses lung cancer screening and smoking cessation and provides participants with a tailored summary that may make them more likely to have shared decision-making discussions with their providers about smoking cessation and lung cancer screening.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
English, Spanish and Cantonese speaking
Age >= 18 years old
Primary care patients at the University of California, San Francisco (UCSF) General Internal Medicine (GIM) clinics
Must be current smokers and/or candidates for Lung Cancer Screening (LCS).
Disqualifiers
Not a current smoker
Trial design
Design model
Sequential
Treatments tested in this trial
Smoking Cessation Intervention
BehavioralMultimedia program administered either remotely or in person
Saliva Collection
Other interventionSaliva samples will be collected from each participant
Survey Administration
Other interventionAncillary studies
Treatment groups
152 Participants
are divided into 3 treatment groupsGroup A: Beta testing (CONNECTing to LungCare, feedback)Other 2 interventions
Group B: Feasibility trial, Group I (CONNECTing to LungCare)Experimental treatment 3 interventions
Group C: Feasibility trial, Group II (usual care)Active comparator 3 interventions
Trial outcomes
Primary outcomes
1
Recruitment rate
The percentage of participants who were contacted and joined the study will be reported.
Time frame
Up to 1 year2
Retention rates
The percentage of participants who joined the study and completed the program will be reported.
Time frame
Up to 1 year3
Adherence rates
The percentage of participants who joined the study and completed all tasks within the program will be reported.
Time frame
Up to 1 year4
Overall time required to recruit to the target sample size (Feasibility Cohort)
The overall time in weeks required to recruit participants for the feasibility cohort will be reported.
Time frame
Up to 1 yearSecondary outcomes
1
Smoking cessation rates
Will evaluate the impact of the intervention on smoking cessation rates. Rates of smoking cessation will be measured by self-report and validated by salivary cotinine levels.
Time frame
At 3 months2
Lung cancer screening (LCS) rates
Rates of LCS will be evaluated through review of the electronic health record (EHR)
Time frame
Up to 3 months3
Shared decision making about LCS
Evidence of shared decision-making conversation will be obtained through one week follow up phone call and with review of the EHR three months after the primary care physician visit.
Time frame
Up to 3 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of California, San Francisco
Lead sponsor
Tobacco Related Disease Research Program
Collaborator
Alere San Diego
Collaborator
Source ClinicalTrials.gov